Industry / Research and Development in Biotechnology
Trending Companies
Latest filings
DEF 14A
IDYA
Ideaya Biosciences
19 Apr 24
Definitive proxy
9:00am
ARS
2023 FY
VIR
Vir Biotechnology
19 Apr 24
Annual report to shareholders
8:40am
DEFA14A
VIR
Vir Biotechnology
19 Apr 24
Additional proxy soliciting materials
8:35am
DEF 14A
VIR
Vir Biotechnology
19 Apr 24
Definitive proxy
8:32am
8-K
VIR
Vir Biotechnology
18 Apr 24
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
8:44am
ARS
2023 FY
RAPT
RAPT Therapeutics
5 Apr 24
Annual report to shareholders
4:11pm
DEFA14A
RAPT
RAPT Therapeutics
5 Apr 24
Additional proxy soliciting materials
4:09pm
DEF 14A
RAPT
RAPT Therapeutics
5 Apr 24
Definitive proxy
4:06pm
144
VIR
Vir Biotechnology
4 Apr 24
Notice of proposed sale of securities
3:34pm
144
VIR
Vir Biotechnology
3 Apr 24
Notice of proposed sale of securities
4:14pm
News
IDEAYA Biosciences Has Selected Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-small Cell Lung Cancer, Based On The Adverse Event Profile And Preliminary Clinical Efficacy
IDYA
22 Apr 24
On April 15, 2024, Sung Lee, Executive Vice President And Chief Financial Officer Of Vir Biotechnology Informed The Company That He Will Be Stepping Down From His Role, Effective May 3, 2024, To Pursue Another Career Opportunity; Co Has Initiated A Search For His Successor
VIR
18 Apr 24
HC Wainwright & Co. Reiterates Neutral on RAPT Therapeutics
RAPT
10 Apr 24
RAPT Therapeutics Highlights Results From Phase 2 Trial Of Tivumecirnon In Combination With Anti-PD-1 Immunotherapy In CPI-Experienced Head And Neck Cancer Patients
RAPT
9 Apr 24
JP Morgan Maintains Neutral on RAPT Therapeutics, Lowers Price Target to $13
RAPT
27 Mar 24
Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $60
IDYA
21 Mar 24
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
VIR
15 Mar 24
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
VIR
15 Mar 24
Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews
IDYA
8 Mar 24
BTIG Initiates Coverage On IDEAYA Biosciences with Buy Rating, Announces Price Target of $55
IDYA
8 Mar 24
Press releases
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
IDYA
22 Apr 24
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
VIR
11 Apr 24
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
RAPT
9 Apr 24
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDYA
5 Apr 24
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
IDYA
1 Apr 24
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
IDYA
12 Mar 24
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
RAPT
11 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
RAPT
11 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
RAPT
7 Mar 24
Patents
Utility
Antibodies and Methods for Treatment of Influenza a Infection
VIR
26 Oct 23
Utility
Antibodies Against SARS-COV-2 and Methods of Using the Same
VIR
19 Oct 23
Utility
Neutralizing anti-influenza b antibodies and uses thereof
VIR
17 Oct 23
Utility
Chemokine Receptor Modulators and Uses Thereof
RAPT
12 Oct 23
Utility
Antibodies That Potently Neutralize Hepatitis B Virus and Uses Thereof
VIR
28 Sep 23
Utility
Cyclized Acetamido Derivatives As Dna Polymerase Theta Inhibitors
IDYA
28 Sep 23
Utility
Piperazine Substituted Indazole Compounds As Inhibitors of Parg
IDYA
28 Sep 23
Utility
Predictive Universal Signatures for Multiple Disease Indications
VIR
7 Sep 23
Utility
Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
VIR
22 Aug 23
Utility
Anticancer agents
RAPT
22 Aug 23
Reddit threads
Daily Discussion Thread - November 9th, 2023
AAOI
ACB
ACDC
9 Nov 23
Daily Discussion Thread - November 8th, 2023
AADI
AAMC
ABSI
8 Nov 23
Daily Discussion Thread - November 2nd, 2023
AAPL
ABCL
ACAD
2 Nov 23
Daily Discussion Thread - August 10th, 2023
LTRY
MOGO
AACG
10 Aug 23
Daily Discussion Thread - August 9th, 2023
AADI
AC
ACET
9 Aug 23
Daily Discussion Thread - August 3rd, 2023
AAOI
AAON
AAPL
3 Aug 23
Daily Discussion Thread - August 2nd, 2023
EXLS
COR
AC
2 Aug 23